If you wish to receive Everest Medicines Limited information by email, please choose your options for email notification, enter your email address and information below and click "Submit".
2021-05-07
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED APRIL 30, 2021
2021-05-07
NEXT DAY DISCLOSURE RETURN
2021-05-06
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON RECEIVING ORPHAN DRUG DESIGNATION FROM THE MINISTRY OF FOOD AND DRUG SAFETY IN SOUTH KOREA FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
2021-04-29
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 1 JUNE 2021
2021-04-29
NOTICE OF ANNUAL GENERAL MEETING
2021-04-29
PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
2021-04-15
VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF SCIENTIFIC OFFICER
2021-04-14
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON US FDA GRANTING LICENSING PARTNER GILEAD SCIENCES, INC. ACCELERATED APPROVAL OF TRODELVY® FOR THE TREATMENT OF METASTATIC UROTHELIAL CANCER
2021-04-12
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2021
2021-04-09
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON LICENSING PARTNER GILEAD SCIENCES, INC. RECEIVING FULL US FDA APPROVAL OF TRODELVY® FOR THE TREATMENT OF PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
